摘要
The journal Genomics Proteomics ＆ Bioinformatics （GPB） is now inviting submissions for a special issue （to be published in June of 2015） on the topic of ＂Biomarkers for Diseases＂. As an emerging index, disease biomarkers have demonstrated the potential application in diagnosis and prognosis. The detection of the disease indicators at molecular level, DNA, RNA, protein or metabolites, could gain highly sensitive and specific signals that truly reflect the pathological changes and fully facilitate diagnostic analysis at early phase with invasive mode. Revolution of high-throughput techniques, such as genome-sequencing and mass spectrometers, greatly promotes the discovery and application of the disease biomarkers. The existing disease biomarkers have covered nearly all the macromolecular categories as well as their variants and modifications, including predisposing genetic variations （such as SNPs）, mutations, epigenetic modifications, miRNAs, splice isoforms, abnormal proteins and autoantibodies. Although some biomarkers have been adopted in clinical practice, there are still great needs for studies on identifying new ones, understanding the existing ones and applying the well-studied ones in practice.
The journal Genomics Proteomics ＆ Bioinformatics （GPB） is now inviting submissions for a special issue （to be published in June of 2015） on the topic of ＂Biomarkers for Diseases＂. As an emerging index, disease biomarkers have demonstrated the potential application in diagnosis and prognosis. The detection of the disease indicators at molecular level, DNA, RNA, protein or metabolites, could gain highly sensitive and specific signals that truly reflect the pathological changes and fully facilitate diagnostic analysis at early phase with invasive mode. Revolution of high-throughput techniques, such as genome-sequencing and mass spectrometers, greatly promotes the discovery and application of the disease biomarkers. The existing disease biomarkers have covered nearly all the macromolecular categories as well as their variants and modifications, including predisposing genetic variations （such as SNPs）, mutations, epigenetic modifications, miRNAs, splice isoforms, abnormal proteins and autoantibodies. Although some biomarkers have been adopted in clinical practice, there are still great needs for studies on identifying new ones, understanding the existing ones and applying the well-studied ones in practice.
